reconsideration and early allowance of all pending claims in light of the following remarks and amendments is courteously requested. The comments presented herein were recently provided to Applicants' attorney by technical personnel associated with the Applicants. These comments were not available prior to the filing of the March 3, 1997 amendment.

Please amend the above-identified application as follows:

In the Claims:

In Claim 1, last line, please insert the word -- primary – before the word "mammalian".

REMARKS

Claims 1-26 are currently rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Walsh (Clin. Res. 39(2):325A, 1991). Applicants contend that the Walsh reference is not an enabling reference. Even if the reference is deemed enabling, Applicants submit that Walsh does not teach the present invention as now claimed. Applicants have amended Claim 1 to specifically recite transduction of a target primary mammalian cell. Claims 2-26 depend, directly or indirectly, from Claim 1. Applicants respectfully submit that the above amendments overcome the rejection.

Specifically, the Walsh abstract only shows use of the AAV vectors in K562 cells. These cells are transformed, cancerous cells that grow indefinitely. In contrast, the present invention is now directed to primary mammalian cells, and not secondary or transformed cells. Applicants respectfully submit that it cannot be predicted how gene expression in transformed cells would translate to primary cells. Thus, Walsh does not provide a teaching reliable to one skilled in the art that the vectors will work in primary cells. The present invention, however, shows that the methods of the present invention will work with primary cells. Accordingly, Applicants respectfully submit that Claims 1-26, as amended, are not anticipated by the Walsh reference and are now in condition for allowance.

Respectfully submitted,



Diane R. Meyers
Registration No. 38,968
Attorney for Applicants

(412) 566-2036